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Citrullination preferentially proceeds in glomerular Bowman’s
capsule and increases in obstructive nephropathy.
Background. Peptidylarginine deiminases (PADs) are a
group of posttranslational modification enzymes that citrulli-
nate (deiminate) protein arginine residues, yielding citrulline
residues. Citrullination of arginine residues abolishes their pos-
itive charge, markedly altering their structure. We undertook
this study to investigate the actions of PADs in the kidney.
Methods. In male rats, we ligated the unilateral ureter, then
analyzed the obstructed and contralateral kidneys 1 week later.
Controls were rats simultaneously given sham operations. In
another experiment, we ligated unilateral ureters of eight rats,
four of which received a ureter-bladder anastomosis 1 week
later. These rats were subjected to histologic examinations
5 weeks after unilateral ureteral obstruction (UUO).
Results. Reverse transcription-polymerase chain reaction
(RT-PCR) revealed that, of PADs (type I, II, III, and IV),
only PAD type II was expressed in kidneys. Western blot study
showed that PAD type II expression and citrullinated protein
content increased greatly in kidneys that underwent unilateral
ureteral ligation compared to that in contralateral or sham-
operated kidneys. Immunohistochemical analyses revealed that
PAD type II was preferentially expressed by parietal epithelial
cells and that only in Bowman’s capsule were proteins citrul-
linated. Additionally, these PAD type II and citrullinated pro-
teins in obstructed nephropathy were significantly attenuated
by the release of the obstruction. Proteome analysis revealed
that one of citrullinated proteins in the kidney should be actin.
Conclusion. This result indicates that PAD type II and citrul-
linated proteins are suitable markers of Bowman’s capsule. Not
only are these markers preferentially expressed in Bowman’s
capsules but their expression is also increased in damaged kid-
neys by UUO, features that promise the further clarification of
kidney diseases.
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Bowman’s capsule, the outer epithelial wall of the
glomerular corpuscle, surrounds glomeruli’s loops and
lobules. In normal conditions, parietal epithelial cells con-
stituting Bowman’s capsule are simple, flat squamous
structures. However, the conformation of parietal epithe-
lial cells variously changes in response to such pathologic
stimuli as ischemia, hypertension, and inflammation. The
result is thickening of the parietal epithelium, and as these
parietal epithelial cells proliferate, they become cuboidal
and form the glomerular crescents that typify some
types of glomerulonephritis. Although Bowman’s capsule
frequently develops this conformation in patients with
kidney diseases, few studies have dealt with it. To date,
protein gene product 9.5 is the only known specific
marker for Bowman’s capsule but this also localizes nerve
fibers around arteries [1].
Peptidylarginine deiminase (PADs) are posttrans-
lational modification enzymes that convert protein
arginine to citrulline residues [2, 3]. Enzymatic citrullina-
tion (deimination) abolishes the positive charge of pro-
tein molecules inevitably causing significant alterations in
their structure and function [4, 5]. These PADs are distinct
from nitric oxide synthetase (NOS) and arginine deimi-
nase, which convert free arginine to citrulline. Mammals
have four types of PADs, designated as type I, type II,
type III, and type IV [6]. Functionally, PADs have been
linked with the pathogenesis of some diseases; for exam-
ple, PAD type IV is the proposed cause of rheumatoid
arthritis and multiple sclerosis [4, 7–9].
Multiple mammalian tissues contain PADs [10] and
PAD expression has tissue specificity; for examples, al-
though all PADs are present in epidermis [6], only PAD
type II is exclusively expressed in brain [9]. Moreover,
citrullination by all PADs shows a definite requirement
for Ca2+ [11]. Although the mRNA of PAD type II and
type IV was previously identified in the rat kidney [6],
whether citrullinated proteins also occupy the kidneys
84
Feng et al: Citrullinated protein as a new marker of Bowman’s capsule 85
remains uncertain. Therefore, in this study, we used a rat
model of kidneys damaged by unilateral ureteral obstruc-
tion (UUO) to assess the expression of PADs and the
presence of citrullinated proteins. As a result, we present
here the first report that specific markers are preferen-
tially expressed in glomerular Bowman’s capsules of the
kidney and that their expression increases in response to
kidney damage.
METHODS
Animals
Male Sprague-Dawley rats (Charles River Breeding
Laboratories, Wilmington, MA, USA), weighing 150 to
180 g, were used in this study. Animals were fed stan-
dard rodent chow and were given water ad libitum. Af-
ter intraperitoneal administration of pentobarbital (5.0
mg/kg body weight) (Dainippon Pharmaceutical Co., Ltd,
Osaka, Japan), anesthetized animals underwent either
left proximal ureteral ligation (N = 6) or, simultane-
ously, a sham operation (N = 6). One week later, the
obstructed (left UUO) kidneys and the contralateral un-
obstructed (right) kidneys as well as normal kidneys
from sham-operated animals were harvested from these
rats. Before removal, the kidneys were well perfused
with approximately 100 mL of normal saline to remove
circulating blood cell fractions or adherent cells. Blood
samples were centrifuged (6000 rpm for 3 minutes) to sep-
arate serum for biochemical measurements. Blood urea
nitrogen (BUN) and serum creatinine were measured by
urease-ultraviolet and enzymatic reaction, respectively
(SRL, Inc., Tokyo Japan).
Ureter-bladder anastomosis
In another animal experiment, eight male Sprague-
Dawley rats (150 to 180 g) were subjected to left UUO.
Four rats of them underwent operation to make ureter-
bladder anastomosis 1 week after the ureteral ligation.
For building the anastomosis, a sterile and nontoxic
polyethylene tube (external diameter 1 mm) (PE-90)
(Clay Adams Intradermic Inc., Sparks, MD, USA) was
inserted to dilated left ureter and the bladder and fixed
securely by silk ligation. These rats were histologically
analyzed 5 weeks after the first UUO operation. Simul-
taneously, the other four rats with UUO for 5 weeks were
examined.
Reverse transcriptase-polymerase chain reaction
(RT-PCR)
The kidney cortex was dissected and homogenized
in Isogen (Nippon Gene, Tokyo, Japan) to isolate total
RNA, followed by treatment with RNase-free DNase
I (Nippon Gene) to remove DNA contamination ac-
cording to the supplier’s protocol. The amount of RNA
extracted was estimated by spectrophotometer. RT-PCR
was performed with a Takara mRNA Selective PCR Kit
(Takara Shuzo Co., Ltd., Kyoto, Japan) according to the
manufacturer’s instructions. RT was performed using
antisense oligonucleotide primers. The primers of rat
PADs type I, type II, type II, type IV, and glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) were designed
as described previously [6]. The sense and antisense
primers were for rat PAD type I, 5′-AGGTATTAGAA
GATGGTGGGGTAGG-3′ and 5′-CCCAACCTTCTC
ATCCCCCTTTA-3′ (expected size 631 bp) [12]; for rat
PAD type II, 5′-ATTCAAGATAGACCAGGAGGA
CCAG-3′ and 5′-CAGAATAGGAAGGCCAGTGTCA
GAA-3′ (expected size 428 bp) [10]; for rat PAD
type III, 5′- CCTTGGCTTGTGCTTCCTATGGT-3′
and 5′-TCCCTCCCTTCTCCCAGTATGTG-3′ (ex-
pected size 648 bp) [6]; for rat PAD type IV, 5′-CGCTC
CTGGCAGCCTCCCTCGAGGA-3′ and 5′-CAGCAT
CTCTAAGCAGGACTGAGTT-3′ (expected size 205
bp) [12]; and for rat GAPDH, 5′-GTGAAGGTCGGT
GTGAACGGAT-3′ and 5′-GCCGCCTGCTTCACCAC
CTTCTT-3′ (expected size 788 bp) [6]. We also followed
PCR conditions as reported with some modifications [6];
30 minutes at 50◦C, and then 15 minutes at 95◦C, followed
by 31 or 32 cycles at 94◦C for 30 seconds, 60◦C for 30
seconds, and 72◦C for 1 minute, and a terminal extension
(72◦C, 10 minutes). We used the same templates from
each experimented kidney for RT-PCR. The condition
of templates was checked by amplification for GAPDH.
A positive control for RT-PCR of PADs was obtained
from rat epidermis where all PADs are expressed [6].
For RT-PCR of PAD type II, mRNA was amplified
by mixing primers of PAD type II and GAPDH. PCR
products were visualized by agarose gel electrophoresis
with ethidium bromide staining. Bands were quantified
by densitometry. GAPDH mRNA was analyzed as an
internal control, and relative amounts of PAD type II
expression were calculated.
Extraction of proteins and Western blotting
Specimens from the renal cortex containing ∼500
mg of protein were sonicated in extraction buffer
[20 mmol/L Tris-HCl, 150 mmol/L NaCl, 2 mmol/L
ethylenediaminetetraacetic acid (EDTA), 1% Nonidet
P40, 50 mmol/L NaF, and 1 mmol/L Na3VO4] with pro-
tease inhibitor cocktail (Roche, Mannheim, Germany)
to extract proteins. Insoluble materials were removed
by centrifugation at 15,000 rpm for 10 minutes. The
supernatants of samples were incubated with the
sample buffer [125 mmol/L Tris-HCl, pH 6.8, 20%
glycerol, 10% 2-mercaptoethanol, 4% sodium dodecyl
sulfate (SDS), 0.005% bromophenol blue (BPB), and
0.005% methylene blue] and heated in boiling water for
5 minutes. Protein concentrations were estimated with
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the BCA Protein Assay Reagent Kit (Pierce, Rockford,
IL, USA). Aliquots (30 lg of crude kidney homogenate)
were resolved by SDS-polyacrylamide gel electrophore-
sis (PAGE) (10% gel) and transferred to polyvinyli-
dene difluoride (PVDF) membranes (Millipore, Bed-
ford, MA, USA). The membranes were blocked with
5% nonfat dried milk in Tris-bufferd saline (100 mmol/L
Tris-HCl/1.4 mol/L NaCl, pH 7.5)/0.1% Tween-20
(TBST) for 1 hour at room temperature before reaction
with the first antibodies. For detection of PAD type II, the
blot was incubated with rabbit antirat PAD type II anti-
serum (×2000) [13]. As a control, the other membrane
was incubated with the same concentration of rabbit
serum instead of anti PAD type II antibody. For detection
of deiminated proteins, we followed a previously reported
protocol [14]. Briefly, citrulline residues on the blot were
chemically modified by overnight incubation at 37◦C in
0.0125% FeCl3, 2.3 mol/L H2SO4, 1.5 mol/L H3PO4,
0.25% diacetyl monoxime, 0.125% antipyrine, and 0.25
mol/L acetic acid (modification medium). As a con-
trol, the other membrane was incubated in the medium
free from diacetyl monoxime and antipyrine. The blot
was then incubated with a monospecific IgG to modi-
fied citrulline (0.125 g/mL) [14]. After reaction with the
first antibody, the bound antibodies were detected using
horseradish peroxidase–conjugated goat anti-rabbit IgG
(PAD type II ×5000, citrulline ×10000) (Bio-Rad Lab-
oratories, Hercules, CA, USA) and enhanced cheminlu-
minescence (ECL) Western blotting detection reagents
(Amersham Biosciences Corp., Piscataway, NJ, USA) ac-
cording to the manufacturer’s instructions. To visualize
total proteins, Coomassie brilliant blue (CBB) staining
was then performed with a Quick-CBB kit (Wako Pure
Chemical Industries, Ltd., Osaka, Japan). The bands of
PAD type II proteins were quantified by densitometry.
The intensity of each band was standardized by the mean
of sham-operated group.
Light microscopy
One week after the operation, we performed histologic
analyses of the kidneys, which had been sufficiently per-
fused for removal of circulating cells from the glomeruli.
For light microscopy, tissue samples were then fixed with
3% formalin-phosphate-buffered saline (PBS) and em-
bedded in paraffin. After sectioning, the tissues were
stained with periodic acid-methenamine-silver (PAM).
PAD staining
Tissue samples from the rats were embedded in
22-oxacalcitriol (OCT) compound (Miles Scientific,
Naperville, IL, USA), and quickly frozen in dry ice-
acetone. Cryostat sections (4 lm) were fixed in cold ace-
tone for 10 minutes. PAD type II was visible after staining
for the indirect fluorescent method. After being washed
with PBS, the sections were incubated with rabbit anti-
PAD type II antiserum [13], followed by rinsing in PBS
and incubation at 37◦C for 60 minutes with rhodamine-
conjugated sheep antirabbit IgG antibody (ICN Pharma-
ceuticals, Inc., Aurora, OH, USA). As controls, the tissues
were incubated with rabbit serum instead of the first an-
tibody. The sections were rinsed again in PBS, mounted
with SlowFade antifade kits (Molecular Probes, Eugene,
OR, USA). No positive staining occurred in control tis-
sues. The degrees of PAD type II staining were calcu-
lated by two methods. At first, we counted the number
of positive glomeruli and expressed them as the percent-
age of all visible glomeruli. In addition, the area posi-
tive for PAD type II in the whole Bowman’s capsule of
a glomerulus was scored semiquantitatively from 0 to 4:
0, negative staining; 1, less than 25%; 2, 25% to 50%; 3,
50% to 75%; and 4, 75% to 100%. We evaluated more
than 30 glomeruli a section and calculated mean value of
each section.
Detection of citrullinated protein in situ
Immunostaining of citrullinated proteins was per-
formed by using antimodified citrulline IgG monoclonal
antibody and a Vectastain Elite ABC kit (PK-6101)
(Vector Laboratories, Inc., Burlingame, CA, USA) as
described previously [15]. This antibody reacts with cit-
rulline residues that are chemically modified. Briefly,
cryosections were post-fixed with 2.5% glutaraldehyde
in PBS and then incubated in the modification medium
(0.0125% FeCl3, 2.3 mol/L H2SO4, 1.5 mol/L H3PO4,
0.25% diacetyl monoxime, 0.125% antipyrine, and 0.25
mol/L acetic acid) at 37◦C overnight to modify citrulline
residues in situ. Control sections were incubated in the
medium free from diacetyl monoxime and antipyrine. Af-
ter washing with PBS, the sections were incubated with
2% bovine serum albumin (BSA)-PBS at room tempera-
ture for 30 minutes to block nonspecific reactions. Then,
they were reacted with anti-modified citrulline antibody
at 37◦C for 2 hours. After washing with PBS, the sec-
tions were next incubated with biotinylated antirabbit
antibody (Vector Laboratories, Inc) at room temperature
for 30 minutes. The sensitivity of this immunostaining was
amplified by Elite ABC mixture. Finally, we incubated
sections in a peroxidase substrate solution made from
buffered substrate for liquid diaminobenzidine (DAB)
(Dako Corporation, Carpinteria, CA, USA) and liquid
DAB chromogen (Dako Corporation) until the desired
stain intensity developed. Staining intensity of citrulli-
nated proteins were analyzed by same ways as scoring of
PAD type II staining.
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Preparation of protein and two-dimensional
gel electrophoresis
Proteins in the kidney were extracted with extrac-
tion buffer (8.5 mol/L urea, 0.2% SDS, 2% Triton X-
100, 3% 2-mercaptoethanol, 0.8% pharmalyte 3-10, 1
mmol/L Na3VO4, and protease inhibitor cocktail), ho-
mogenized and centrifuged for 10 minutes at 15,000 rpm.
The cytosolic fraction (supernatant) was separated by two
dimensional electrophoresis performed in an immobi-
lized pH gradients (IPG)-isoelectric focusing (IEF)/SDS-
PAGE system according to the standard protocol
found on the Web page http://proteome.tmig.or.jp/2D/
2DE method.html with minor modification. In brief, IEF
was performed on IPG, pH 4 to 7, 180 mm (Amersham
Biosciences AB, Uppsala, Sweden)] with CoolPhorestar
model 3610 Horizontal IEF apparatus (Anatech, Tokyo,
Japan). The IPG gels were incubated in rehydrating
buffer [6 mol/L urea, 2 mol/L thiourea, 13 mmol/L dithio-
threitol (DTT), 0.8% pharmalyte 3-10, 2.5 mmol/L acetic
acid, 0.0025% (wt/vol) orangeG, and 2% (vol/vol) Tri-
ton X-100] overnight. The protein samples (100 lg) were
absorbed in a small piece of filter paper and they were ap-
plied near the cathode wick on the IPG gel. After 600 to
700 V/hour at 20◦C of electrofocusing, the IPG gels were
incubated for 30 minutes in equilibration buffer [6 mol/L
urea, 33 mmol/L DTT, 25 mmol/L Tris-HCl (pH6.8), 2%
(wt/vol) SDS, 0.0025% (wt/vol) BPB, and 30% (vol/vol)
glycerol], followed by a 20-minute incubation in equili-
bration buffer [25 mmol/L Tris-HCl, pH 6.8, 2% (wt/vol)
SDS, 0.0025% (wt/vol) BPB, 30% (vol/vol) glycerol, and
0.243 mol/L idoacetamide].
Separation of the second dimension was performed in
precast 7.5% SDS/polyacrylamide gel [Tris/Tricine, 200
× 200mm (Anatech)] using the CoolPhoreStar SDS-
PAGE Dual-200 vertical slab gel electrophoresis appa-
ratus (Anatech). SDS-PAGE was carried out at 25 mA
per gel for 5 hours. After electrophoresis, proteins were
stained with Sypro ruby gel stain (Molecular Probes, Inc.)
following the manufacturer’s protocol and visualized by
Molecular Imager FX (Bio-Rad, Tokyo, Japan).
Mass spectrometry
Protein spots exicised from two-dimensional elec-
trophoresed gels were destained and subjected to di-
gestion with sequence-grade modified trypsin (Sigma
Chemical Co., St. Louis, MO, USA) at 30◦C overnight.
The digested peptides was mixed with equal volumes
of matrix (10 mg/mL a-cyano-4-hydroxy-trans-cinnamic
acid in 50% acetonitrile, 40% methanol, and 0.1% tri-
fluoroacetic acid) and applied to a matrix-assisted laser
desorption/ionization (MALDI) targed plate. Pepetide
mass was analyzed using AXIMA CFR MALDI time-
of-flight (MALDI-TOF) mass spectrometer (Shimadzu,
Kyoto, Japan). The spectra were obtained in the positive-
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Fig. 1. Biochemical parameters 1 week after operations. Blood urea
nitrogen (BUN) levels (A) were significantly increased in the unilateral
ureteral obstruction (UUO)-treated rats () (20.5 ± 1.25 mg/dL) above
those in recipients of sham-operation () (12.9 ± 0.83 mg/dL) (P <
0.01). Similarly, serum creatinine (Cr) (B) of UUO group () (0.29 ±
0.02 mg/dL) was significantly elevated compared with that of the sham-
operated group () (0.19 ± 0.01 mg/dL) (P < 0.01).
ion reflector mode with delayed extraction. External cal-
ibration was performed using des-Arg-bradykinin [M +
H]+ = 904.5 (monoisotopic), and adrenocorticotropic
hormone (ACTH) [M + H]+ = 2465.7 (monoisotopic).
Peptide mass fingerprinting [phenylmethylsulfonyl fluo-
ride (PMSF)] database search was performed by sending
the list of observed masses to MASCOT search engine
http://www.matrixscience.com/
Statistical analysis
All values are expressed as means ± SEM. Statisti-
cal significance between groups was determined by the
unpaired t test. P values less than 0.05 were considered
statistically significant.
RESULTS
Renal damage was induced by UUO
One week after surgery to place ureteral obstructions
in the left kidneys of rats (N = 6), serum levels of BUN
and creatinine were measured to confirm whether the
UUO procedure caused subsequent renal failure. Serum
BUN levels in these animals were significantly greater
than those in sham-operated group (N = 6) (20.5 ± 1.25
mg/dL vs. 12.9 ± 0.83 mg/dL) (P < 0.001) (Fig. 1). Simi-
larly, serum creatinine levels in the UUO group exceeded
those in the sham-operated group (0.29 ± 0.02 mg/dL vs.
0.19 ± 0.01 mg/dL) (P < 0.01) (Fig. 1).
Histologically, renal tissues of sham-operated rats ap-
peared normal under the light microscope (Fig. 2A
and B). One week after surgery, glomeruli in the right
(contralateral), unobstructed kidneys of UUO group
were almost normal (Fig. 2C), whereas glomeruli of the
obstructed left kidneys were shrunken, with cuboidal
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Fig. 2. Light microscopic findings 1 week
after the operations. Under the light mi-
croscope, periodic acid-methenamine-silver
(PAM) staining of kidney sections 1 week
after unilateral ureteral obstruction (UUO)
or sham-operation (Sham) showed that
glomeruli and interstitium from right kidneys
(A) and left kidneys (B) of sham-operated rats
were normal. Similarly, unobstructed right
kidneys from rats whose left kidneys received
UUO had normal glomeruli (C). However,
in UUO-treated left kidneys (D), not only
interstitial expansion was observed, but also
thickened Bowman’s capsules and cuboidal
changes of parietal epithelial cells (original
magnifications ×200).
parietal epithelium and fibrosis around Bowman’s cap-
sule (Fig. 2D). The expansion of interstitial area was
also observed in the obstructed kidneys. These results
present a clear picture of surgically induced obstructive
nephropathy.
PAD type II mRNA was detected in kidney samples
The expression of PAD mRNAs was assessed by RT-
PCR using individual primers for rat PAD type I, type II,
type III, and type IV. However, no mRNA of PAD type
I or type III was detected in samples from obstructed,
contralateral or healthy control kidneys (Fig. 3B and C,
lanes 1 to 4). Because mRNAs of the same samples from
experimentally manipulated kidneys were amplified by
primers of GAPDH (Fig. 3A, upper bands of lanes 1 to 5),
and positive controls from epidermis expressing all PADs
(Fig. 3A to D, lane 5) were also amplified by primers of
PAD type I and type III, we verified that these samples
were suitable for detection of the mRNA of interest. Like
PAD types I and III, PAD type IV mRNA was seldom
expressed in obstructed, contralateral or healthy control
kidneys (Fig. 3D, lanes 1 to 4). Again, the suitability of
extracted mRNA and primers of PAD type IV (Fig. 3A
to D, lane 5) for these assays was confirmed. In contrast
to the foregoing results in which PAD type I, III, and IV
were not expressed, PAD type II mRNA was detected in
all samples from the cortexes of normal as well as dam-
aged kidneys (Fig. 3A, lanes 1 to 4). Relative PAD type II
mRNA expression (PAD type II/GAPDH) is the highest
in the left kidney with the obstruction (Fig. 3E).
Amounts of PAD type II protein increased in
obstructed kidneys
Next, expression of PAD type II was examined by
Western blot analysis. As shown in Figure 4, PAD type
II protein was only minimally detectable in kidneys of
sham-operated rats and the right contralateral kidneys
of the UUO group (Fig. 4A, sham left and UUO right).
However, PAD type II protein of approximately 70 kD
was observed in the left kidneys of the UUO group
(Fig. 4A, UUO left). The specificity of rabbit anti-PAD
type II antibody used to identify the protein was recon-
firmed when no bands were detectable with rabbit serum
used as a first antibody instead of anti-PAD type II anti-
body (Fig. 4C). Additionally, the extracted proteins were
stained by CBB (Fig. 4B and D). When protein bands
were quantified by densitometry, PAD type II protein was
significantly increased in obstructed kidneys (Fig. 4E).
Obstructed kidneys developed large increases in
citrullinated proteins
The expression of the PAD type II does not always cat-
alyze citrullination, because this reaction requires Ca2+.
However, Western blot analysis using specific antibody
against modified citrulline residues successfully yielded
bands of approximately 70 kD, 60 kD, and 40 kD, de-
noting the presence of citrullinated proteins on chemi-
cally treated membranes only in obstructed kidneys of the
UUO group (Fig. 5A, UUO left). To the contrary, in the
kidneys of sham-operated rats and contralateral kidneys
of the UUO animals, no such bands appeared (Fig. 5A,
sham left and UUO right). Because this antibody does
not react with unmodified citrulline, we can certify the
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Fig. 3. Expression of glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) (A),
peptidylarginine deiminases (PAD) type
I (B), type II (A), type III (C), and type
IV (D) transcripts in rat kidneys. Total
RNA was isolated from the cortexes of
rat kidneys, and the same templates from
experimented kidneys were amplified by
reverse transcription-polymerase chain
reaction (RT-PCR) using each primer. Lane
1, right kidney with sham-operation; lane
2, left kidney with sham-operation; lane 3,
right (contralateral) kidney with unilateral
ureteral obstruction (UUO) treatment; lane
4, left kidney (obstructed) kidney with UUO;
lane 5, positive control from rat epidermis.
Expected sizes of amplified sequences based
on primer design were 631 bp for PAD type
I, 428 bp for PAD type II, 648 bp for PAD
type III, 205 bp for PAD type III, and 788
bp for GAPDH. All PADs transcripts were
observed in epidermal samples and all sam-
ples were amplified by primers of GAPDH.
PAD type II mRNA was detected only in
kidney tissue, regardless of obstruction or
lack thereof (A). PAD type I (B), III (C),
and IV (D) mRNA were merely detected in
samples from obstructed, contralateral, or
healthy control kidneys. Relative amount of
PAD type II mRNA expression (PAD type
II/GAPDH) is the highest in left kidneys with
the obstruction (E). Values are mean ± SEM.
specificity of this antibody by staining membranes with-
out chemical treatment. As shown in Fig. 5C, no bands
emerged on the membrane without chemical modifica-
tion. The extracted proteins were stained by CBB staining
(Fig. 5B and D).
PAD type II protein was preferentially expressed in pari-
etal epithelial cells of kidneys damaged by obstruction
but not in normal kidneys
By immunohistochemical analysis, PAD type II expres-
sion was barely noticeable along the parietal epithelia of
normal rat kidneys (Fig. 6A and B, Sham) or in unob-
structed kidneys (Fig. 6C, UUO right). On the other hand,
PAD type II expression was marked in parietal epithelia
of tissue undergoing obstructive nephropathy 1 week af-
ter the UUO operation (Fig. 6D, UUO left). No PAD type
II expression was observed except on glomerular parietal
epithelial cells. As shown in Table 1, 1 week after UUO,
intensity of PAD type II expression in Bowman’s cap-
sules and percentages of PAD type II–positive glomeruli
were significantly increased in left kidneys of UUO group
(UUO left 1 week) compared with those of contralateral
kidneys (UUO right 1 week) or sham-operated kidneys
(Sham left).
Citrullinated protein is preferentially present along
Bowman’s capsule
When we proceeded with staining to identify citrulli-
nated proteins in situ, almost no citrullinated proteins ap-
peared in kidneys of sham-operated rats (Fig.7A and B).
Sometimes, a few citrullinated proteins lay along Bow-
man’s capsule in a very small number of glomeruli of
the sham-operated group. Similarly, citrullinated proteins
were scarce in right contralateral kidneys of the UUO
group (Fig. 7C). To the contrary, citrullinated proteins
were visible along Bowman’s capsule of the obstructed
left kidneys (Fig. 7D). When we stained rat kidney tissues
without chemical treatment by the modification medium,
no positive staining was seen at all (Fig. 7E to H). There-
fore, the specificity of the antibody used was reconfirmed
histochemically, and this procedure showed that PAD
type II and citrullinated proteins both lodged preferen-
tially along Bowman’s capsules of damaged kidneys by
UUO. One week after UUO, staining intensity for citrul-
linated proteins in Bowman’s capsules and percentages
of positive glomeruli were markedly higher in the left ob-
structed kidneys of UUO group than right unobstructed
kidneys or sham-operated kidneys (Table 1).
Citrullination decreased by the release of ureteral
obstruction
To investigate whether citrullination reflects kidney
damages by UUO, ureter-bladder anastomosis was made
1 week after the UUO operation. Glomeruli of the
left kidneys with UUO for 5 weeks had cuboidal pari-
etal epithelium and periglomerular fibrosis around Bow-
man’s capsule (Fig. 8A). Four weeks after the release of
ureteral obstruction, glomeruli returned to normal, and
its parietal epithelium became flat (Fig. 8B). This light
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Fig. 4. Western blot for peptidylarginine
deiminases (PAD) type II. A total 30 lg of iso-
lated proteins from kidney cortexes was trans-
ferred to polyvinylidine difluoride (PVDF)
membranes. Bands positive for PAD type II
scarcely appeared in sham-operated (Sham-
left) or unobstructed kidneys of unilateral
ureteral obstruction (UUO) group (UUO-
right). In contrast, a clear band at approxi-
mately 70 kD was observed in left kidneys 1
week after UUO (UUO-left) (A). Thereafter,
the membrane was stained by Coomassie bril-
liant blue (CBB) (B). Although bands at ap-
proximately 60 kD and 80 kD were more in-
tense in left kidneys of the UUO group than
others, intensities of other bands were simi-
lar. When the membranes stained by rabbit
serum as a first antibody instead of anti PAD
type II antibody, no bands were visible (C).
Therefore, the band in (A) is specific. That
membrane was stained by CBB (D). When
protein bands were quantified by densitom-
etry, PAD type II amount was significantly
increased in left obstructed kidneys (UUO-
left) compared with that in sham-operated
kidneys (Sham-left) or contra-lateral kidneys
(UUO-right) (Fig 4E). ∗P < 0.01 versus sham-
operated kidneys and right contra-lateral kid-
neys with UUO. Values are mean ± SEM.
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Fig. 5. Western blot for detection of citrul-
linated proteins. A total 30 lg of proteins
isolated from kidney cortex was transferred
to polyvinylidine difluroride (PVDF) mem-
branes. For detection, monoclonal antibody
was added to react chemically with modified
citrulline. One membrane was treated with the
modification medium before the reaction with
anti-modified citrulline antibody, and then cit-
rullinated proteins were stained as described
in the Methods section (A), followed by
Coomassie brilliant blue (CBB) staining (B).
Citrullinated proteins were detected only in
obstructed kidneys (UUO-left) (A). Another
membrane was stained by same first antibody
and second antibody without chemical mod-
ification as a control (C), followed by CBB
staining (D). No bands of citrullinated pro-
teins were observed in the membrane without
chemical modification (C), which indicated
specific reaction of first antibody to chemically
modified citrulline.
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Sham
UUO
Right Left
Fig. 6. Peptidylarginine deiminases (PAD)
type II expression on abnormal Bowman’s
capsules. Kidney tissues were stained by rab-
bit antirat PAD type II antiserum. (A) Right
kidney of sham-operated group. (B) Left kid-
ney of sham-operated group. (C) Right kid-
ney of unilateral ureteral obstruction (UUO)
group. (D) Left kidney with ureteral obstruc-
tion of UUO group. In both sides of kidneys
in sham-operated group, PAD type II expres-
sion was miniscule (A and B). In contralat-
eral, unobstructed kidney (right), the expres-
sion was also scarce (C). On the other hand,
in left kidneys staining for PAD type II was
positive and located preferentially in parietal
epithelial cells of Bowman’s capsules (D). G is
a glomerulus (original magnifications ×200).
Table 1. Summary of histologic examinations (the semiquantitative values of staining intensity and percentages of positive glomeruli for
peptidylarginine deiminase (PAD) type II and citrullinated proteins
PAD II Citrullinated protein
Group Intensity % Intensity %
Sham left (N = 6) 0.63 ± 0.14 36.9 ± 3.7 0.13 ± 0.04 9.2 ± 2.9
UUO right 1 week (N = 6) 0.76 ± 0.12 40.7 ± 4.5 0.08 ± 0.03 8.1 ± 2.7
UUO left 1 week (N = 6) 3.64 ± 0.13a,c 100 ± 0a,c 1.71 ± 0.06a,c 92.1 ± 1.8a,c
UUO left 5 week (N = 4) 4.00 ± 0.00a,c 100 ± 0a,c 3.02 ± 0.24a,c,d 100 ± 0a,c,d
Bypass left 5 week (N = 4) 2.61 ± 0.22a,c,d,e 80.1 ± 3.8a,b,c,d,e 0.33 ± 0.06b,c,d,e 27.8 ± 6.0b,c,d,e
UUO is unilateral ureteral obstruction; Bypass left 5 weeks, the data from rats receiving ureter-bladder bypass 1 week after UUO and then living for 4 weeks. The
calculation methods of staining intensity and percentages were explained in the Methods section. Values are mean ± SEM. Statistical significance between groups was
determined by the unpaired t test.
aP < 0.01 versus sham; bP < 0.05 versus sham; cP < 0.01 versus right contralateral kidneys of UUO group for 1 week (UUO right 1week); dP < 0.01 versus left
obstructed kidneys after 1-week ligation (UUO left 1weed); eP < 0.01 versus left obstructed kidneys after 5 weeks of UUO (UUO left 5 weeks).
microscopic study showed that the lesions in Bowman’s
capsules with UUO were attenuated by the ureter-
bladder anastomosis to release the ureteral obstruction.
Five weeks after UUO operation, PAD type II expression
was strongly observed in the whole parietal epithelial cells
(Fig. 8C) (Table 1). This intense expression of PAD type II
was significantly attenuated by the release of ureteral ob-
struction (Fig. 8D) (Table 1). Citrullinated proteins were
also increased in Bowman’s capsules of obstructed kid-
neys for 5 weeks (Fig. 8E) (Table 1). However, when we
performed the operation for release of UUO 1 week af-
ter the ureteral ligation, the citrullinated proteins were
diffusely decreased below those in kidneys with UUO
for 5 weeks. Furthermore, PAD type II and citrullinated
proteins were also significantly diminished in the left
kidneys of the group that underwent the ureter-bladder
bypass operation even compared with those in the left
obstructed kidneys for 1 week, in which these pro-
teins were already increased in Bowman’s capsules
(Table 1).
Actin filaments should be citrullinated in the kidney
Next, two-dimensional electrophoresis was performed
to investigate what proteins were citrullinated in the
kidney. We obtained two spots which were citrullinated
(Fig. 9). Their molecular weights were both approxi-
mately 40 kD. The MALDI mass fingerprint spectrums
of these spots at 40 kD (Fig. 10A) were analyzed by the
MASCOT search engine. The results showed that citrul-
linated proteins at 40 kD were actins (Fig. 10B).
DISCUSSION
This report describes for the first time that PAD type
II and citrullinated proteins are suitable markers for
Bowman’s capsules, since their expression occurs pref-
erentially in Bowman’s capsules of the renal glomeruli
and increases markedly during the course of obstructive
nephropathy.
For this study, we adapted a model of obstructive renal
damage by unilaterally ligating the left ureter (UUO) in
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Fig. 7. Detection of citrullinated protein in
situ. Citrullinated proteins were detected by
modification of citrulline residues in tissues
followed by staining with anti modified cit-
rulline antibody. (A and E) Right kidney of
sham-operated group. (B and F) Left kidney
of sham-operated group. (C and G) Right un-
obstructed kidney of unilateral ureteral ob-
struction (UUO) group. (D and H) Left ob-
structed kidney of UUO group. When tissues
were stained after chemical modification (A
to D), both sides of sham-operated group and
right kidney of UUO group did not show pos-
itive staining for citrullinated proteins (A to
C). Only in the left obstructed kidney of the
UUO group was protein citrullination was
preferentially detected in Bowman’s capsule,
which appeared like rings (D). When tissues
were not chemically modified (E to H), no
positive staining followed (original magnifica-
tions ×200).
each of six rats and simultaneously performed sham op-
erations as a control (N = 6). UUO increases fluid pres-
sure in the urinary tract, thereby also increasing pressure
in tubuli and Bowman’s space. This model has been used
often to study the mechanisms of renal fibrosis [16]. In the
glomeruli, UUO makes parietal epithelial cells of Bow-
man’s capsule receive tension as mechanical stress. In this
study, UUO of the rat urinary tract caused renal failure
within 1 week, as confirmed by increases of serum BUN
and creatinine (Fig. 1). In addition, the obstructed kid-
neys had thickening of Bowman’s capsules and cuboidal
formation of the parietal epithelial cells (Fig. 2).
The results of RT-PCR to identify PADs indicated that
neither PAD type I nor type III was expressed in any kid-
neys, whether normal, UUO operated, or sham operated
(Fig. 3). Similarly, PAD type IV was rarely detected in any
of these kidneys (Fig. 3), and even this limited expression
of PAD type IV mRNA seemed to come from circulat-
ing leukocytes left after presurgical perfusion, because
these cells do express PAD type IV [17]. A marked dif-
ference was the expression of PAD type II mRNA found
in both right and left kidneys of the UUO group and the
sham-operated group (Fig. 3). Therefore, we judged that
renal cells express only type II of the four known PAD
types. When we measured the densities of bands and cal-
culated relative amounts of PAD type II mRNA/GAPDH
mRNA, amounts in the rats’ left obstructed kidneys were
significantly higher than in any other samples of kid-
neys from sham-operated rats or right kidneys from the
UUO group (Fig. 3E). This increase of PAD type II in
obstructed kidneys was confirmed by Western blot of
protein levels (Fig. 4). Sham-operated and unobstructed
kidneys had only negligible levels of PAD type II, whereas
the bands of PAD type II were readily detected at the ex-
pected molecular weight in all obstructed kidneys from
the UUO group. Therefore, PAD type II is expressed by
renal cells, and the amount increases after ureteral block-
age (Fig. 4E). In addition, glomerular parietal epithelial
cells of obstructed kidneys preferentially express PAD
type II, but those of normal kidneys (Fig. 6). Because
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Fig. 8. Representative sections stained for
periodic acid-Schiff (PAS) (A and B), pep-
tidylarginine deiminases (PAD) type II (C
and D), and citrullinated protein (E and F)
of rats that lived with unilateral ureteral ob-
struction (UUO) for 5 weeks (A, C, and
E) or that received operation to release the
ureteral obstruction by ureter-bladder bypass
2 week after UUO operation and then lived
for 4 weeks (B, D, and F). Under light micro-
scope, although glomeruli of obstructed kid-
neys had thickened Bowman’s capsules and
cuboidal changes of parietal epithelium (A),
these changes returned to normal in rats re-
ceiving bypass operation, in which parietal ep-
ithelial cells were simple and flat squamous
(B). PAD type II expression was strongly
observed preferentially in parietal epithelial
cells around the whole Bowman’s capsule of
rats with UUO (C). On the other hand, pari-
etal epithelial cell of rats with the ureter-
bladder bypass expressed much less PAD type
II (D). Similarly, citrullinated proteins were
clearly detected preferentially in Bowman’s
capsules of rats with UUO for 5 weeks (E). By
the ureter-bladder bypass, citrullinated pro-
teins in Bowman’s capsules were apparently
decreased (F).
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Fig. 9. Sypro ruby stained protein map of
rat kidney with unilateral ureteral obstruc-
tion (UUO). A total of 100 lg protein was
separated using 18 cm pH 4 to 7 immobilized
pH gradients (IPG) and 7.5% sodium dode-
cyl sulfate-polyacrylamide gel electrophore-
sis (SDS-PAGE). The proteins were resolved
by differential isoelectric point (pI) for the
first dimensional running (x axis) and differ-
ential molecular weight (MW) for the sec-
ond dimension (y axis). Proteins were stained
with sypro ruby gel stain. To detect citrul-
linated protein, after sypro ruby staining of
two-dimensional electrophoresis gel, proteins
were transferred onto polyvylidine difluoride
(PVDF) membrane and incubated with anti-
body. Two protein spots were detected (spot 1,
2). Enlarged region of sypro ruby stained two-
dimensional electrophoresis gel are in right
side. Sypro ruby staining is shown in the up-
per side and staining for citrullinated protein
is shown in lower side.
the right unobstructed kidneys from UUO-treated rats
scarcely expressed PAD type II, the significant increase
of PAD type II only in the left obstructed kidneys (Table
1) evidently arose from the mechanical stress of ureteral
obstruction, not circulating factors.
PADs catalyze the citrullination reaction, which con-
verts protein arginine to citrulline residues in a Ca2+-
dependent manner [11]. Possibly related is a previous re-
port that endothelin and platelet-activating factor (PAF)
act on the parietal sheet of Bowman’s capsule by increas-
ing intracellular concentrations of Ca2+ [18]. In addition,
endothelin and PAF were induced by ureteral obstruction
[16, 19]. On the basis of those reports, presumably in-
tracellular Ca2+ concentrations rise in parietal epithelial
cells of Bowman’s capsule after ureteral obstruction, and
this elevated concentration would be available to func-
tion with PAD type II in the increased catalysis of pro-
tein citrullination at that site (Fig. 7). Therefore, when we
assessed our three groups of kidneys with Western blot-
ting, citrullinated proteins were detected only in kidneys
with ureteral obstruction (Fig. 5). Although PAD type II
expression was clearly detected in cytoplasms of parietal
epithelial cells, we could not decide whether citrullinated
proteins were located in the parietal epithelium or the
basement membrane of Bowman’s capsules. In future,
immunoelectron microscopy will reveal the location.
Our studies using UUO model for 1 week indicated
that citrullination occurs preferentially in Bowman’s cap-
sules of the renal glomeruli and increases markedly
during the course of obstructive nephropathy. Next, to
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Fig. 10. Identification of protein spots by
matrix-assisted laser desorption/ionization
time-of flight (MALDI/TOF) mass spec-
trometry analysis. MALDI mass fingerprint
spectrum of spot 2 was shown in the up-
per (A). Peptide mass fingerprinting was
performed using the MASCOT search en-
gine (www.matrixscience.com) based on the
SWISS-PROT database. Results of the search
are shown in the bottom. Protein spot 2 was
identified as actin (B) and spot 1 was also actin
[SWISS-PROT accession no. P60711 (data not
shown)].
investigate whether expression of PAD type II and citrul-
linated proteins reflects damages of Bowman’s capsules
by ureteral obstruction, a ureter-bladder anastomosis to
release the obstruction was made 1 week after UUO op-
eration. Four weeks after the bypass, the appearance of
Bowman’s capsules returned to normal under the light
microscope (Fig. 8B). On the other hand, Bowman’s cap-
sules of kidneys 5 weeks after UUO were severely thick-
ening and had cuboidal epithelial cells (Fig. 8A). By the
ureter-bladder bypass, PAD type II expression of pari-
etal epithelial cells was significantly decreased compared
with that in UUO kidneys not only for 5 weeks but also for
1 week (Fig. 8) (Table 1). Similarly, citrullinated proteins
were also markedly attenuated in kidneys with the bypass
compared with those in kidneys with UUO for 5 weeks
and for 1 week (Fig. 8) (Table 1). These results indicate
that besides being markers of Bowman’s capsules, PAD
type II, and citrullinated proteins can reflect the damages
of Bowman’s capsules. In crescentic glomerulonephritis,
Bowman’s capsules become similarly cuboidal. There-
fore, we histologically examined rats that were induced
crescentic glomerulonephritis by rabbit antiglomerular
basement membrane antibody to investigate whether cit-
rullination in Bowman’s capsules participates in cuboidal
formation of parietal epithelial cells. Our study showed
that PAD type II and citrullinated proteins were not
detected in their Bowman’s capsules (data not shown).
Therefore, although it was speculated that increment of
citrullination in Bowman’s capsules should specifically
occur in response to mechanical stress to glomeruli, it re-
mains to be solved what roles citrullination in the kidney
plays.
Western blotting (Fig. 5) located several sites of cit-
rullinated proteins in the obstructed kidneys examined
here. To explain the roles of citrullination in the kid-
ney, we performed proteome analysis of these citrulli-
nated proteins. By two-dimensional electrophoresis, two
protein spots which were citrullinated were obtained
(Fig. 9). Their molecular weights were approximately
40 kD although main band was present at approximately
60 kD rather than 40 kD in Western blotting for cit-
rullinated proteins (Fig. 5). The analysis of mass finger-
print spectra of these spots at 40 kD revealed that these
were actins (Fig. 10). Although we wanted to identify the
60 kD citrullinated protein, the protein could not be de-
tected by two-dimensional electrophoresis (Fig. 9), prob-
ably caused by technical difficulties. Therefore, we think
these proteome analyses are now incomplete. In future,
60 kD citrullinated proteins should be identified to ex-
plain further fundamental roles of citrullination in kid-
neys. Previous reports described intermediate filaments
of cytoskeletal proteins such as keratin and vimentin
that were also citrullinated [20, 21]. Such citrullination
abolished the positive charge of protein molecules, in-
evitably causing significant alteration in their structure
[4, 5]. Therefore, if citrullinated proteins in Bowman’s
capsule are cytoskeletal proteins, that would explain de-
fense mechanism of Bowman’s capsule against mechani-
cal stress to glomeruli.
Only one suitable marker of Bowman’s capsule has
been reported previously [1]. Our study described here
greatly extends that report by indicating that PAD
type II and citrullinated proteins are preferentially ex-
pressed in Bowman’s capsules and, additionally, that their
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expression increases in damaged kidneys by ureteral ob-
struction. These newfound markers of Bowman’s capsule
are expected to broaden the experimental possibilities for
research on kidney diseases.
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